Medical management of persistent and recurrent cushing disease.
Neurosurg Clin N Am
; 23(4): 653-68, 2012 Oct.
Article
en En
| MEDLINE
| ID: mdl-23040750
ABSTRACT
Recent evidence supports the notion that the incidence of Cushing disease is higher than previously thought. Transphenoidal surgery, in the hands of experienced neurosurgeons, is currently considered the first-line treatment of choice. However, an examination of remission and recurrence rates in long-term follow-up studies reveals that potentially up to 40% to 50% of patients could require additional treatment. If left untreated, the resultant morbidity and mortality are high. Successful clinical management of patients with Cushing disease remains a challenge. The development of new therapeutic agents has been eagerly anticipated. This article discusses the results of currently available and promising new therapeutic agents used to treat this challenging disease.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Hipófisis
/
Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT)
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Neurosurg Clin N Am
Asunto de la revista:
NEUROCIRURGIA
Año:
2012
Tipo del documento:
Article
País de afiliación:
Estados Unidos